Vitamin B12 Market Size & Share 2026-2035

Vitamin B12 Market Size

The global Vitamin B12 market was valued at USD 811.7 million in 2026 and is projected to reach USD 1.5 billion by 2035, expanding at a CAGR of 6.8% from 2026 to 2035. According to the latest report published by Global Market Insights Inc., demand is shifting from a largely commodity-led vitamin supply chain toward differentiated food, supplement, pharmaceutical, and feed applications.

The commercial divide is clearest between high-volume cyanocobalamin and premium methylcobalamin. That distinction changes both attainable price points and supplier qualification requirements.

The market covers pure cobalamin-equivalent ingredients, APIs, and finished-product demand across food fortification, dietary supplements, pharmaceuticals, and animal nutrition. It excludes vitamin complexes where B12 demand cannot be isolated. Revenue rose from USD 620.4 million in 2022 to USD 760 million in 2025, a 7.02% historic CAGR. Volume reached 0.0152 kilo tons in 2025 and will grow at 5.3% through 2035, below revenue growth as higher-value forms gain mix. Estimates use triangulation across application demand, regional procurement patterns, supplier portfolios, and competitive shares.

Key Drivers

Plant-based diets increase reliance on fortified foods and supplements because B12 occurs predominantly in animal-sourced foods. The World Health Organization identifies a material deficiency burden, particularly among older adults and populations with low animal-product intake.^{[1]World Health Organization, “Vitamin B12 Deficiency Prevalence,” who.int} This supports repeat demand across single-ingredient supplements, B-complex products, and fortified staples. The most commercial effect falls on suppliers that can provide stable forms for diverse food matrices.

Food and beverage formulators are also making B12 a visible functional ingredient. EFSA’s Nutrient Reference Value of 2.5 micrograms per day remains a central formulation reference in Europe.^{[2]European Food Safety Authority, “Vitamin B12 Nutrient Reference Value,” efsa.europa.eu} Consumer supplement use supplies a parallel demand base: 74% of U.S. adults reported using dietary supplements in CRN’s 2024 survey. Functional beverages and plant-based dairy alternatives therefore widen consumption occasions without requiring a clinical diagnosis.

Aging creates a durable pharmaceutical and therapeutic demand pool. The global population aged 65 and over will rise from 771 million in 2022 to 1.6 billion by 2050.^{[3]United Nations, “World Population Prospects 2022,” un.org} Injectable and high-dose oral products benefit where clinical protocols address reduced dietary absorption. This channel rewards qualified API supply and established hospital distribution.

Key Restraints

Commercial B12 production depends on tightly managed microbial fermentation and downstream purification. Smaller producers face a structural cost disadvantage when they lack scale, multi-product platforms, or established export certification. Commodity competition can therefore compress margins even as total demand expands. Larger Chinese suppliers have reinforced the cost-led supply tier, while multinational suppliers defend margins through specialty forms and application support.

B12 stability can complicate processing and shelf-life management in fortified foods. Light, heat, oxygen exposure, and reactive food matrices can require encapsulation, controlled packaging, or formulation adjustments. Those requirements raise development costs for brands using B12 in beverages and food products. The restraint favors suppliers with technical support capabilities instead of undifferentiated bulk offerings.

Vitamin B12 Market Segment Analysis

By Type

Cyanocobalamin accounted for 52% of 2025 revenue, or USD 395.2 million, and will grow at a 6.4% CAGR through 2035. Its broad food and pharmaceutical acceptance under FDA food standards and EU Regulation 1925/2006 sustains its role in high-volume fortification.^{[4]U.S. Food and Drug Administration, “21 CFR Parts 182 and 101,” fda.gov} The main commercial sub-segments are 0.1% and 1% spray-dried formats on maltodextrin or mannitol, plus crystalline powder. These formats align with cereal premixes, tablet cores, injection inputs, and infant nutrition applications.

Methylcobalamin represented 26% of revenue, or USD 197.6 million, and will expand at a 7.4% CAGR. Pharmaceutical-grade and supplement-grade material serve different customer needs, but both benefit from the form’s direct biological activity and premium neurological-health positioning. Research cited in the American Journal of Clinical Nutrition supports the clinical distinction between methylcobalamin and cyanocobalamin.^{[5]Tucker K. L. et al., “Plasma Vitamin B-12 Concentrations Relate to Intake Source in the Framingham Offspring Study,” American Journal of Clinical Nutrition, academic.oup.com/ajcn} DSM-Firmenich’s VALIDA® platform demonstrates how branded methylcobalamin can turn technical differentiation into higher-value supplement demand.

Adenosylcobalamin generated USD 38.0 million, or 5% of 2025 revenue, but carries the highest type-level CAGR at 9.4%. Pharmaceutical-grade and supplement-grade products address metabolic medicine and premium combination nutraceuticals. Its small base limits volume influence, yet the form improves supplier relevance in specialized therapeutic and mitochondrial-energy formulations. CSPC’s full cobalamin portfolio, including cobamamide, strengthens its position in this niche.

Hydroxocobalamin held 17% of 2025 revenue, equivalent to USD 129.2 million, and will grow at 6.1% annually. Injectable-grade material drives its therapeutic role, while oral and supplement-grade products serve a smaller wellness market. European hospital formularies favor compliance-assured supply for injectable use. The segment’s durable clinical demand partly offsets its more limited retail visibility.

By Application

Food Fortification led application demand at 32%, or USD 243.2 million, and will grow at a 7.3% CAGR. Breakfast cereals, plant-based milk and beverages, bakery products, and staple foods form the core sub-segments. Brazil’s ANVISA RDC 429/2020 and India’s FSSAI Fortification Regulation 2016 reinforce policy-linked demand for compliant micronutrient formulations.^{[6]Brazil ANVISA, “RDC 429/2020,” anvisa.gov.br} Mandatory programs reduce exposure to discretionary spending cycles and make reliable food-grade supply strategically important.

Dietary Supplements accounted for USD 205.2 million, or 27% of revenue, and will expand at 6.5% annually. Multivitamin/mineral, B-complex, single-ingredient B12, and prenatal/postnatal products are the principal sub-segments. Methylcobalamin has the strongest pricing opportunity here because consumers can distinguish form, delivery method, and clinical positioning. Supplement brands increasingly use sublingual formats and direct-to-consumer programs to separate premium products from commodity tablets.

Pharmaceuticals represented 23% of demand, or USD 174.8 million, and will post the highest application CAGR at 7.5%. Intramuscular and subcutaneous injections remain the principal formats, followed by oral tablets, capsules, sublingual preparations, and intranasal gels and sprays. Fresenius Kabi’s Cyanocobalamin Injection, USP, under ANDA080557, illustrates the qualification threshold in the U.S. clinical segment. Demographic aging supports demand, but regulatory documentation and manufacturing quality determine access.

Animal Feed & Nutrition held 18%, or USD 136.8 million, and will grow at 5.3% annually. Poultry, swine, ruminant, and aquaculture feed make up the application base. Feed-grade demand favors cyanocobalamin cost efficiency, although certified products such as ROVIMIX® B12 1% Feed Grade retain a quality-differentiated position. The segment provides steady volumes but faces sharper price pressure than pharmaceuticals and supplements.

By Distribution Channel

Direct Sales (B2B) controlled 58% of 2025 revenue, or USD 440.8 million, and will grow at 6.5% annually. Large food, pharmaceutical, and contract-supplement manufacturers use direct contracts to secure specifications, traceability, and continuity of supply. Distributors & Wholesalers accounted for 27% and serve smaller manufacturers, compounding pharmacies, and laboratory users needing documentation and inventory flexibility. Retail Channels represented 8.5% and remain relevant for finished supplements. E-commerce & Online Platforms held 6.5%, or USD 49.4 million, yet will expand at 11.9% annually as subscription models, brand websites, and marketplace access reshape consumer purchasing. The channel shift creates direct demand visibility for finished-product brands such as NOW Foods.

Vitamin B12 Market Regional Analysis

North America

North America generated USD 205.2 million in 2025, representing 27% of global revenue, and will reach USD 384.6 million by 2035 at a 6.48% CAGR. The U.S. anchors demand through supplement use, FDA labeling and food standards, and a developed injectable market.^{[7]Council for Responsible Nutrition, “2024 Consumer Survey on Dietary Supplements,” crnusa.org} Canada’s natural-health-product framework supports a structured premium supplement channel. The regional constraint is mature penetration in conventional tablets, which raises the importance of premium forms, digital distribution, and functional foods.

Europe

Europe held USD 182.4 million, or 24% of global revenue, in 2025 and will grow at 6.35% through 2035. Germany’s BfR intake guidance, EU food-information rules, and EFSA’s reference value frame product development across Germany, the UK, France, Italy, Spain, and the rest of Europe.^{[8]German Federal Institute for Risk Assessment, “Vitamin B12 Maximum Daily Intake Guidance,” bfr.bund.de} The region combines premium plant-based food demand with high-value injectable procurement. Its constraint is an exacting compliance environment that raises qualification costs but protects established suppliers.

Asia

Asia Pacific is the largest regional market at USD 281.2 million and 37% share in 2025, rising to USD 563.6 million by 2035 at a 7.20% CAGR. China combines production scale with domestic food, feed, and pharmaceutical demand, led by suppliers including CSPC, Ningxia Kingvit, Zhejiang NHU, and NCPC Kangxin. India’s FSSAI framework provides a policy-based fortification demand source.^{[9]Food Safety and Standards Authority of India, “Fortification of Foods Regulations, 2016,” fssai.gov.in} Japan supports higher-value pharmaceutical and nutraceutical consumption, while South Korea and Australia contribute premium supplement demand. Regional competition will remain intense because production capacity and local demand expand simultaneously.

Latin America

Latin America accounted for USD 53.2 million, or 7% of global revenue, in 2025 and will reach USD 121.8 million by 2035 at an 8.64% CAGR. Brazil leads demand, with Mexico and Argentina following. ANVISA’s RDC 429/2020 strengthens the regional case for processed-food fortification. The region’s low revenue base explains part of its growth rate, but policy-backed procurement makes the expansion commercially durable. Price sensitivity will still favor food-grade cyanocobalamin over premium therapeutic forms.

Middle East & Africa

MEA generated USD 38.0 million in 2025, or 5% of global revenue, and will grow at 4.65% to USD 60.2 million by 2035. The UAE and Saudi Arabia provide the most developed supplement and pharmaceutical distribution channels, while South Africa supplies a material Sub-Saharan demand base. Healthcare infrastructure and clinical access remain uneven across the region.^{[10]World Bank, “Middle East and Africa Healthcare Infrastructure,” worldbank.org} This limits premium-form penetration even as pharmaceutical demand rises in Gulf markets.

Vitamin B12 Market Share & Competitive Landscape

The market is moderately concentrated. DSM-Firmenich led with an estimated 15% share in 2025, followed by BASF SE at approximately 13%, CSPC at approximately 6%, and Ningxia Kingvit at approximately 5%; the top five collectively held approximately 42%. The competitive structure combines multinational ingredient leaders, Chinese fermentation and API manufacturers, injectable specialists, laboratory suppliers, compounders, and consumer brands.

DSM-Firmenich differentiates through certified supply, VALIDA® methylcobalamin, and ROVIMIX® feed products. Its April 2025 methylcobalamin capacity expansion at Sisseln demonstrates a direct commitment to premium-tier growth. BASF competes through 0.1% and 1% spray-dried products, microencapsulated forms, and distribution across more than 60 countries. CSPC, operating through Hebei Huarong, offers the full cobalamin range and received FDA acknowledgment for its cyanocobalamin injectable API Drug Master File in February 2025. Ningxia Kingvit combines a pure-B12 capacity base with pharmaceutical, food, and feed certifications across export markets.

Recent Industry Developments

• Apr 2025: DSM-Firmenich expanded methylcobalamin production capacity at Sisseln, Switzerland. The investment supports premium ingredient supply for European functional-food and supplement customers.

• Feb 2025: CSPC Pharmaceutical Group received U.S. FDA acknowledgment for a cyanocobalamin injectable API Drug Master File. The action broadens its access to regulated pharmaceutical procurement.

• Nov 2024: NKF received FDA registration approval for Vitamin B12 injection. The development reinforces its role in the U.S. injectable supply chain.